MDXG News and Press, MiMedx Group Inc From 02/11/24

2024-02-11 02:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-01-31 10:16:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-01-22 08:48:29 ET More on MiMedx Group MiMedx Group: Restructuring Changes Are Paying Off MiMedx Group, Inc. (MDXG) Q3 2023 Earnings Call Transcript MiMedx gets FDA warning letter over Axiofill production MiMedx adds 30M shares on conversion of preferred...

MARIETTA, Ga., Jan. 22, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it has enhanced its capital structure by refinancing its existing indebtedness and obtaining additional borrowing capacity in support of ...

2024-01-05 13:25:00 ET Summary Today, we take a deeper look at MiMedx Group, Inc., a wound care company focused on developing and distributing placental tissue allografts. The company is already benefiting from a restructuring of its business in June that helped MiMedx beat expect...

Boston, Massachusetts--(Newsfile Corp. - January 3, 2024) - Block & Leviton is investigating MiMedx Group, Inc. (NASDAQ: MDXG) for potential securities law violations. Investors who have lost money in their MiMedx Group, Inc. investment should contact the firm  to learn more about how t...

2023-12-29 18:01:59 ET More on MiMedx Group MiMedx Group, Inc. (MDXG) Q3 2023 Earnings Call Transcript Unraveling MiMedx's Surgical Precision In Growth MiMedx adds 30M shares on conversion of preferred stock MiMedx Group Non-GAAP EPS of $0.05 in-line, revenue...

Receipt of FDA Warning Letter for AXIOFILL Classification; Not Related to Safety Request for Designation for AXIOFILL Submitted to FDA and Currently Under Review Reiterates Expectations for 2023 Net Sales Growth in the High Teens and Fourth Quarter Adjusted EBITDA Margin of Abov...

2023-12-28 08:30:35 ET More on MiMedx Group MiMedx Group, Inc. (MDXG) Q3 2023 Earnings Call Transcript Unraveling MiMedx's Surgical Precision In Growth MiMedx Group Non-GAAP EPS of $0.05 in-line, revenue of $81.71M beats by $3.77M Seeking Alpha’s Quant...

MARIETTA, Ga., Dec. 28, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that its outstanding 95,000 shares of Series B Convertible Preferred Stock (the “Preferred Stock”), together with any accrued di...